贲门胃底癌患者术前升压化疗的临床病理特点及预后因素分析  

THE PROGNOSIS FACTOR ANALYSIS AND CLINICAL PATHOLOGICAL FEATURE OF PREOPERATIVE INDUCED HYPERTESION CHEMOTHERAPY ON THE Ⅲ STAGING CARDIA OR FUNDUS OF STOMACH CARCINOMA

作　　者：翟建文[1] 华文霞[1] 姜素英[1] 

机构地区：[1]河北工程大学临床医学院,邯郸056002

出　　处：《现代预防医学》2008年第17期3439-3440,3444,共3页Modern Preventive Medicine

基　　金：邯郸市科研基金资助(02115-3)

摘　　要：[目的]分析术前升压化疗治疗Ⅲ期贲门胃底癌的临床病理特点及预后因素,为这一综合治疗方法提供可靠的理论依据。[方法]选取术前化疗的Ⅲ期贲门胃底癌患者49例,其中升压化疗组19例,单纯化疗组30例。二组患者术后标本进行病理组织学观察及流式细胞仪测定。[结果]FCM测定升压化疗组的DNA两倍体明显高于单纯化疗组,两组S期细胞比值有显著性差异。升压化疗组术后1、3年生存率明显高于单化组。[结论升压化疗治疗Ⅲ期贲门胃底癌安全有效,可明显改善预后,提高术后生存率。[ Objective] To analyze the prognosis factor and clinical pathological feature of preoperative hypertesion chemotherapy on the Ⅲ staging cardia or fundus of stomach carcinoma and provide reliable theory basis for therapy. [ Methods ] Selected preoperative chemotherapeutic 49 cases of Ⅲ staging cardia or fundus of stomach carcinoma. 19 cases were in preoperative hypertesion chemotherapy group, 30 cases were in simple chemotherapy group. The postoperative specimens in two groups were carried out pathohistology observation and flow cytometry. [Results] DNA ploid determination in hypertesion chemotherapy group was obviously higher than that in simple chemotherapy group. There was significant difference between the two groups in the ratios of S period cell. [Conclusion] The hypertesion chemotherapy on the Ⅲ staging cardia or fundus of stomach carcinoma is safe and effective. It can obviously improve prognosis and increase postoperative survival rate.

关 键 词：Ⅲ期贲门胃底癌 升压化疗 流式细胞术 预后 

分 类 号：R735.2[医药卫生—肿瘤]